Compare NREF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | ELDN |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.2M | 291.8M |
| IPO Year | N/A | 2014 |
| Metric | NREF | ELDN |
|---|---|---|
| Price | $15.25 | $3.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.00 | $8.50 |
| AVG Volume (30 Days) | 37.9K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.95% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.47 | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.36 | $1.35 |
| 52 Week High | $16.06 | $4.60 |
| Indicator | NREF | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 57.51 |
| Support Level | $13.76 | $2.52 |
| Resistance Level | $16.04 | $4.60 |
| Average True Range (ATR) | 0.46 | 0.22 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 52.41 | 59.59 |
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.